KR102281550B1 - 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도 - Google Patents

아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도 Download PDF

Info

Publication number
KR102281550B1
KR102281550B1 KR1020197004529A KR20197004529A KR102281550B1 KR 102281550 B1 KR102281550 B1 KR 102281550B1 KR 1020197004529 A KR1020197004529 A KR 1020197004529A KR 20197004529 A KR20197004529 A KR 20197004529A KR 102281550 B1 KR102281550 B1 KR 102281550B1
Authority
KR
South Korea
Prior art keywords
amino
phenyl
nicotinamide
azabicyclo
hexan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197004529A
Other languages
English (en)
Korean (ko)
Other versions
KR20190026917A (ko
Inventor
지아량 리
루카 아리스타
스리하리 바부
지안웨이 비안
카이 쿠이
마이클 패트릭 딜런
렌 라트만
레브 리아오
디미트리오스 리조스
리타 라모스
니콜라우스 요하네스 슈티플
토마스 울리히
페기 유셀만
시아오양 왕
릴라드하르 무를리드하르 웨이콜
스벤 바일러
유보 장
이종 조우
팅잉 주
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority to KR1020217022916A priority Critical patent/KR102359707B1/ko
Publication of KR20190026917A publication Critical patent/KR20190026917A/ko
Application granted granted Critical
Publication of KR102281550B1 publication Critical patent/KR102281550B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020197004529A 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도 Active KR102281550B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217022916A KR102359707B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
US62/364,620 2016-07-20
PCT/CN2017/093385 WO2018014829A1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217022916A Division KR102359707B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도

Publications (2)

Publication Number Publication Date
KR20190026917A KR20190026917A (ko) 2019-03-13
KR102281550B1 true KR102281550B1 (ko) 2021-07-27

Family

ID=60991950

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020197004529A Active KR102281550B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020227034980A Active KR102559539B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020227003660A Active KR102454129B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020217022916A Active KR102359707B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020237024969A Active KR102667331B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020247016068A Active KR102719881B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020247034434A Pending KR20240155367A (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020227034980A Active KR102559539B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020227003660A Active KR102454129B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020217022916A Active KR102359707B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020237024969A Active KR102667331B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020247016068A Active KR102719881B1 (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR1020247034434A Pending KR20240155367A (ko) 2016-07-20 2017-07-18 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도

Country Status (25)

Country Link
US (4) US10710980B2 (enExample)
EP (3) EP3971177B1 (enExample)
JP (4) JP7030776B2 (enExample)
KR (7) KR102281550B1 (enExample)
CN (2) CN114014844B (enExample)
AR (1) AR109108A1 (enExample)
AU (5) AU2017298187B2 (enExample)
CY (1) CY1124967T1 (enExample)
DK (2) DK3971177T3 (enExample)
EA (2) EA037520B1 (enExample)
ES (2) ES2902521T3 (enExample)
FI (1) FI3971177T3 (enExample)
HR (2) HRP20241015T1 (enExample)
HU (2) HUE067992T2 (enExample)
LT (2) LT3971177T (enExample)
MX (2) MX388518B (enExample)
PL (2) PL3487851T3 (enExample)
PT (2) PT3487851T (enExample)
RS (2) RS62819B1 (enExample)
RU (1) RU2747318C2 (enExample)
SI (2) SI3487851T1 (enExample)
SM (2) SMT202100723T1 (enExample)
TW (4) TWI851226B (enExample)
UY (1) UY37331A (enExample)
WO (1) WO2018014829A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210094138A (ko) * 2016-07-20 2021-07-28 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022009710A2 (pt) * 2019-11-22 2022-08-09 Incyte Corp Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
CA3187767A1 (en) * 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
KR102913358B1 (ko) * 2020-10-29 2026-01-14 주식회사 엘지화학 중수소화 화합물의 분석방법, 소자 제조용 중수소화 화합물의 선별방법 및 전자 소자의 제조방법
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN116478145B (zh) * 2022-04-13 2024-02-02 杭州邦顺制药有限公司 Alk2激酶抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084455A1 (en) * 2006-01-17 2007-07-26 Schering Corporation Hydantoin compounds for the treatment of inflammatory disorders
WO2014138088A1 (en) 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2014151871A2 (en) 2013-03-14 2014-09-25 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
WO1994011502A2 (en) 1992-11-17 1994-05-26 Ludwig Institute For Cancer Research Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2004230519A1 (en) 2003-04-11 2004-10-28 Sgx Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
MXPA06013786A (es) 2004-05-27 2007-01-25 Pfizer Nuevos derivados de aminopiridina y su uso como farmacos.
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
JPWO2006109876A1 (ja) 2005-04-08 2008-11-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 不随意運動治療剤
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US8895711B2 (en) 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
US20080021024A1 (en) 2006-06-29 2008-01-24 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
EP2062048A4 (en) 2006-09-12 2009-12-02 Gen Hospital Corp METHOD FOR IDENTIFYING CELL SIGNALING MODULATING COMPOUNDS AND METHOD FOR USING SUCH COMPOSITES
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
WO2012023113A2 (en) 2010-08-20 2012-02-23 Wyeth Llc Designer osteogenic proteins
KR20140014104A (ko) 2010-12-06 2014-02-05 피라말 엔터프라이지즈 리미티드 치환된 이미다조퀴놀린 유도체
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CA2832605C (en) 2011-05-23 2016-03-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
US9550000B2 (en) 2011-09-09 2017-01-24 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP2900238B1 (en) 2012-09-28 2017-12-06 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
KR20160063366A (ko) 2013-10-21 2016-06-03 메르크 파텐트 게엠베하 Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도
US10260068B2 (en) 2014-03-31 2019-04-16 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
EP3247701B1 (en) 2015-01-20 2021-09-22 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds, compositions and method of using thereof
BR112018004065B1 (pt) 2015-08-31 2023-12-12 Dong-A Socio Holdings Co., Ltd Compostos heterocíclicos, composições farmacêuticas compreendendo os ditos compostos e usos terapêuticos dos mesmos
US11462835B2 (en) 2016-07-20 2022-10-04 Qorvo Us, Inc. Method for tuning an antenna with a DVC
JP7030776B2 (ja) * 2016-07-20 2022-03-07 ノバルティス アーゲー アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084455A1 (en) * 2006-01-17 2007-07-26 Schering Corporation Hydantoin compounds for the treatment of inflammatory disorders
WO2014138088A1 (en) 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2014151871A2 (en) 2013-03-14 2014-09-25 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210094138A (ko) * 2016-07-20 2021-07-28 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR20220021023A (ko) * 2016-07-20 2022-02-21 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR102454129B1 (ko) * 2016-07-20 2022-10-14 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR20220143770A (ko) * 2016-07-20 2022-10-25 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR102559539B1 (ko) * 2016-07-20 2023-07-26 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR20230117248A (ko) * 2016-07-20 2023-08-07 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의용도
KR102667331B1 (ko) 2016-07-20 2024-05-21 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도

Also Published As

Publication number Publication date
JP7253086B2 (ja) 2023-04-05
CN114014844B (zh) 2024-10-01
TWI755255B (zh) 2022-02-11
JP7030776B2 (ja) 2022-03-07
JP2019521167A (ja) 2019-07-25
RS66041B1 (sr) 2024-11-29
RU2021111037A (ru) 2021-05-13
US10947218B2 (en) 2021-03-16
US20200299265A1 (en) 2020-09-24
EP4442317A2 (en) 2024-10-09
UY37331A (es) 2018-02-28
EA201990343A1 (ru) 2019-06-28
ES2902521T3 (es) 2022-03-28
TW202134228A (zh) 2021-09-16
PL3971177T3 (pl) 2024-10-28
AU2021201424A1 (en) 2021-03-25
AR109108A1 (es) 2018-10-31
TWI712598B (zh) 2020-12-11
RU2019104609A3 (enExample) 2020-09-30
TW202220969A (zh) 2022-06-01
CY1124967T1 (el) 2023-01-05
KR20210094138A (ko) 2021-07-28
KR20230117248A (ko) 2023-08-07
TWI806385B (zh) 2023-06-21
KR20190026917A (ko) 2019-03-13
AU2023200265A1 (en) 2023-02-16
CA3030332A1 (en) 2018-01-25
CN109641871B (zh) 2021-10-22
HUE057328T2 (hu) 2022-05-28
EP3487851A4 (en) 2019-12-25
KR102454129B1 (ko) 2022-10-14
JP7584553B2 (ja) 2024-11-15
DK3971177T3 (da) 2024-07-15
RU2021111037A3 (enExample) 2022-02-10
EP3971177B1 (en) 2024-06-26
KR20240074904A (ko) 2024-05-28
JP2022078137A (ja) 2022-05-24
PL3487851T3 (pl) 2022-04-11
TW201805277A (zh) 2018-02-16
KR102559539B1 (ko) 2023-07-26
US20190161474A1 (en) 2019-05-30
AU2024205058A1 (en) 2024-08-15
EA202190285A1 (ru) 2021-08-31
RU2747318C2 (ru) 2021-05-04
US10710980B2 (en) 2020-07-14
MX388518B (es) 2025-03-19
KR20240155367A (ko) 2024-10-28
JP2025032086A (ja) 2025-03-11
AU2017298187A1 (en) 2018-12-20
KR102667331B1 (ko) 2024-05-21
EP3971177A1 (en) 2022-03-23
ES2984746T3 (es) 2024-10-30
US20260116869A1 (en) 2026-04-30
HUE067992T2 (hu) 2024-12-28
CN114014844A (zh) 2022-02-08
EA037520B1 (ru) 2021-04-07
PT3971177T (pt) 2024-07-30
AU2019246857B2 (en) 2020-12-24
CN109641871A (zh) 2019-04-16
RU2019104609A (ru) 2020-08-20
HRP20211868T1 (hr) 2022-03-04
EP3487851B1 (en) 2021-10-20
BR112019000941A2 (pt) 2019-04-30
PT3487851T (pt) 2022-01-07
JP2023089012A (ja) 2023-06-27
TWI851226B (zh) 2024-08-01
US20210155606A1 (en) 2021-05-27
HRP20241015T1 (hr) 2024-11-08
MX2019000837A (es) 2019-07-04
JP7834830B2 (ja) 2026-03-24
LT3487851T (lt) 2021-12-27
AU2019246857A1 (en) 2019-10-31
RS62819B1 (sr) 2022-02-28
TW202509017A (zh) 2025-03-01
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
SI3487851T1 (sl) 2022-03-31
SMT202100723T1 (it) 2022-01-10
AU2021201424B2 (en) 2022-10-20
KR20220021023A (ko) 2022-02-21
TW202336011A (zh) 2023-09-16
EP4442317A3 (en) 2025-01-01
SMT202400335T1 (it) 2024-09-16
FI3971177T3 (fi) 2024-07-30
SI3971177T1 (sl) 2024-10-30
KR102719881B1 (ko) 2024-10-23
WO2018014829A1 (en) 2018-01-25
KR20220143770A (ko) 2022-10-25
LT3971177T (lt) 2024-08-26
KR102359707B1 (ko) 2022-02-09
AU2023200265B2 (en) 2024-08-15
US12466808B2 (en) 2025-11-11
MX2021014852A (es) 2022-01-18
DK3487851T3 (da) 2021-12-20
EP3487851A1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
US20260116869A1 (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
RU2826177C1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
HK40069664B (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40117528A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
CA3030332C (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40069664A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40007022B (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
EA051808B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
EA049492B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
EA045493B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20190215

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190215

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200928

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210420

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210720

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210720

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210721

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240619

Start annual number: 4

End annual number: 4